Cardiothoracic patients have a high risk of surgical site infection. The overall incidence is between 0.5% and 6%, but that increases to 12-20% among high risk patients, such as those with diabetes or who are obese. Collatamp G can provide greater than 50% reduction in sternal wound infections.3
Studies show that when used dry prior to insertion; gentamicin-containing collagen implants such as Collatamp G significantly reduce the rate of surgical site infections following cardiac surgery. Collatamp G is particularly beneficial in high risk patients, such as those with diabetes or who are obese. Use of Collatamp G is shown to shorten the recovery phase and length of hospital stay, and reduce the need for surgical revision and use of antibiotics.
Collatamp G has also been shown to help in the treatment of deep sternal wound infections. Sternal wound infections are associated with high mortality rates of 14% to 47%, and are reported to occur with an incidence of approximately 0.5% to 8%. In studies, Collatamp G has been shown to decrease the risk of deep sternal wound infections 66%. Collatamp G is implanted retrosternally without pre-moistening after the preliminary placement of sternal wiring. Then sternal wiring is performed. Because Collatamp G is placed directly into the wound during surgery, it delivers a high dose of powerful antibiotic directly at the site of infection risk. Then the collagen breaks down and is easily resorbed by the body, avoiding the risk of systemic toxicity and associated side effects.